<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460304</url>
  </required_header>
  <id_info>
    <org_study_id>07-01</org_study_id>
    <nct_id>NCT00460304</nct_id>
  </id_info>
  <brief_title>The Effect of Pramlintide on Meal Time Insulin Bolus</brief_title>
  <official_title>The Effect of Pramlintide on Meal Time Insulin Bolus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Care Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Diabetes Care Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to establish the mean percentage of change in the
      insulin-to-carbohydrate ratio due to pramlintide treatment once a maximum tolerated dose or 6
      mcg before each meal is reached. The secondary objective is to establish which insulin bolus
      wave form is associated with the lowest post-bolus without hypoglycemia in subjects treated
      with maximum pramlintide dosage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pramlintide. an amylinomimetic, is effective in reducing post-meal glucose by non-insulin
      means. As such, when patients requiring insulin treatment are treated with pramlintide, the
      bolus insulin does must be reduced. Current recommendations suggest a 50% reduction but in
      our experience and that of a recent study this appears excessive. By using continuous glucose
      monitoring(CGM) to guide pre-meal insulin treatment, we will determine the percentage
      reduction in meal time insulin bolus comparing pre-pramlintide to maximum pramlintide
      treatment. We anticipate that the reduction in bolus dosage will be about 25%. In addition,
      the secondary aim of this study is to determine which bolus pattern, standard, square or dual
      wave, provides the best post-meal glucose control with pramlintide therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.</measure>
    <time_frame>12-10-07</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.</measure>
    <time_frame>12-10-07</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramlintide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>continuous glucose monitoring</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;17

          -  Type I diabetes

          -  Onset of diabetes &gt;3 months

          -  Use of insulin pump &gt;3 months

          -  Hb A1C &lt;8.9%

          -  Demonstrated compliance to clinic visits

          -  Demonstrated knowledge and use of bolus dosing calculations, carbohydrate counting,
             use of insulin pump and blood glucose meter

          -  Monitor blood glucose &gt;4/day

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Recent (within last 3 months) factor that may cause change in insulin sensitivity,
             e.g. severe emotional or physical stress, recent significant infection or surgery.
             etc.

          -  Renal failure (creatinine &gt;1.5 mg/dl

          -  Symptomatic gastroparesis

          -  Using a medication that would interfere with insulin sensitivity

          -  Treatment with extenatide or DPP IV inhibitor within the last 4 weeks

          -  HbA1C change &gt;0.9 % within the last 3 months

          -  Significant change in eating or activity pattern

          -  Weight change of &gt;1.9 kg within the last 3 months

          -  ALT &gt;3 times upper limits of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen B King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Care Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary S Wolfe, RN, CCM</last_name>
    <role>Study Director</role>
    <affiliation>Diabetes Care Center</affiliation>
  </overall_official>
  <reference>
    <citation>Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct;29(10):2189-95.</citation>
    <PMID>17003291</PMID>
  </reference>
  <reference>
    <citation>Symlin (package insert) San Diego, CA Amylin Pharmacetucials. 2005</citation>
  </reference>
  <reference>
    <citation>King AB, Armstrong DU. Basal bolus dosing: a clinical experience. Curr Diabetes Rev. 2005 May;1(2):215-20. Review.</citation>
    <PMID>18220597</PMID>
  </reference>
  <reference>
    <citation>King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: Basal dosing. J Diabetes Sci Technol. 2007 Jan;1(1):36-41.</citation>
    <PMID>19888377</PMID>
  </reference>
  <reference>
    <citation>King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007 Jan;1(1):42-6.</citation>
    <PMID>19888378</PMID>
  </reference>
  <reference>
    <citation>Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995 Jun;38(6):642-8.</citation>
    <PMID>7672483</PMID>
  </reference>
  <reference>
    <citation>Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997 Jan;46(1):67-70.</citation>
    <PMID>9005972</PMID>
  </reference>
  <reference>
    <citation>Rushing PA, Lutz TA, Seeley RJ, Woods SC. Amylin and insulin interact to reduce food intake in rats. Horm Metab Res. 2000 Feb;32(2):62-5.</citation>
    <PMID>10741687</PMID>
  </reference>
  <reference>
    <citation>Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther. 2000;2 Suppl 1:S19-26.</citation>
    <PMID>11469628</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <keyword>Type I diabetes</keyword>
  <keyword>Insulin pump</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <keyword>Insulin to carbohydrate ratio</keyword>
  <keyword>Correction factor</keyword>
  <keyword>Pramlintide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 17, 2011</submitted>
    <returned>July 18, 2011</returned>
    <submitted>August 23, 2013</submitted>
    <returned>October 27, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

